Ubrelvy (Ubrogepant) Patent Expiration, LOE Window & CMS Spending

Ubrelvy (Ubrogepant) by AbbVie: FDA Orange Book core substance LOE 2033-12-23 (last listed 2041-12-22), 0 AB generics, $738.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN211765 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-12-23
Last Listed Patent or Exclusivity Date2041-12-22
Orange Book Patents (*PED Extensions)16 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$738.2M
2024 Medicare Part D Spend$429.5M
2024 Medicaid Spend$308.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.